Literature DB >> 22021335

Peroxisome proliferator-activated receptor-β/δ, the acute signaling factor in prostacyclin-induced pulmonary vasodilation.

Yingji Li1, Michelle Connolly, Chandran Nagaraj, Bi Tang, Zoltan Bálint, Helmut Popper, Freyja M Smolle-Juettner, Jörg Lindenmann, Grazyna Kwapiszewska, Philipp I Aaronson, Christoph Wohlkoenig, Katharina Leithner, Horst Olschewski, Andrea Olschewski.   

Abstract

As powerful vasodilators, prostacyclin analogues are presently the mainstay in the treatment of severe pulmonary arterial hypertension. Although the hemodynamic effects of prostacyclin analogues are well known, the molecular mechanism of their acute effects on pulmonary vascular tone and systemic vascular tone remains poorly understood. Peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) was previously identified as a putative receptor responsible for the modulation of target gene expression in response to prostacyclin analogues. The present study investigated the signaling pathway of prostacyclin in human pulmonary arterial smooth muscle cells (PASMCs), and sought to define the role of PPARβ/δ in the acute vasodilating effect. In human PASMCs, prostacyclin rapidly activated TWIK-related acid-sensitive K channel 1 (TASK-1) and calcium-dependent potassium channels (K(Ca)). This pathway was mediated via the prostanoid I receptor-protein kinase A pathway. The silencing of PPARβ/δ demonstrated that the downstream K(Ca) activation was exclusively dependent on PPARβ/δ signaling, whereas the activation of TASK-1 was not. In addition, the PPARβ/δ-induced activation of K(Ca) was independent of NO. The acute prostacyclin-induced K(Ca) activation is critically dependent on PPARβ/δ as a rapid signaling factor. This accounts in part for the vasodilating effect of prostacyclin in pulmonary arteries, and provides insights into a new molecular explanation for the effects of prostanoids.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22021335     DOI: 10.1165/rcmb.2010-0428OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  13 in total

1.  International Union of Basic and Clinical Pharmacology. CIX. Differences and Similarities between Human and Rodent Prostaglandin E2 Receptors (EP1-4) and Prostacyclin Receptor (IP): Specific Roles in Pathophysiologic Conditions.

Authors:  Xavier Norel; Yukihiko Sugimoto; Gulsev Ozen; Heba Abdelazeem; Yasmine Amgoud; Amel Bouhadoun; Wesam Bassiouni; Marie Goepp; Salma Mani; Hasanga D Manikpurage; Amira Senbel; Dan Longrois; Akos Heinemann; Chengcan Yao; Lucie H Clapp
Journal:  Pharmacol Rev       Date:  2020-10       Impact factor: 25.468

2.  Docosahexaenoic acid causes rapid pulmonary arterial relaxation via KCa channel-mediated hyperpolarisation in pulmonary hypertension.

Authors:  Chandran Nagaraj; Bi Tang; Bence M Nagy; Rita Papp; Pritesh P Jain; Leigh M Marsh; Andrea L Meredith; Bahil Ghanim; Walter Klepetko; Grazyna Kwapiszewska; E Kenneth Weir; Horst Olschewski; Andrea Olschewski
Journal:  Eur Respir J       Date:  2016-08-18       Impact factor: 16.671

3.  The peroxisome proliferator-activated receptor β/δ agonist GW0742 has direct protective effects on right heart hypertrophy.

Authors:  Baktybek Kojonazarov; Himal Luitel; Akylbek Sydykov; Bhola K Dahal; Mark J Paul-Clark; Sara Bonvini; Anna Reed; Ralph T Schermuly; Jane A Mitchell
Journal:  Pulm Circ       Date:  2013-12       Impact factor: 3.017

4.  Administration of prostacyclin modulates cutaneous blood flow but not sweating in young and older males: roles for nitric oxide and calcium-activated potassium channels.

Authors:  Naoto Fujii; Sean R Notley; Christopher T Minson; Glen P Kenny
Journal:  J Physiol       Date:  2016-09-23       Impact factor: 5.182

5.  Regulation of ca(2+) signaling in pulmonary hypertension.

Authors:  Amy L Firth; Jun Yeon Won; Won Sun Park
Journal:  Korean J Physiol Pharmacol       Date:  2013-02-14       Impact factor: 2.016

6.  Mechanisms of endothelium-dependent relaxation evoked by anandamide in isolated human pulmonary arteries.

Authors:  Marta Baranowska-Kuczko; Hanna Kozłowska; Mirosław Kozłowski; Eberhard Schlicker; Monika Kloza; Arkadiusz Surażyński; Emilia Grzęda; Barbara Malinowska
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-02-28       Impact factor: 3.000

7.  Prostacyclin analogue beraprost inhibits cardiac fibroblast proliferation depending on prostacyclin receptor activation through a TGF β-Smad signal pathway.

Authors:  Yun Chen; Shengju Yang; Wenjuan Yao; Hongyan Zhu; Xiaole Xu; Guoliang Meng; Wei Zhang
Journal:  PLoS One       Date:  2014-05-22       Impact factor: 3.240

8.  Role of prostacyclin in pulmonary hypertension.

Authors:  Jane A Mitchell; Blerina Ahmetaj-Shala; Nicholas S Kirkby; William R Wright; Louise S Mackenzie; Daniel M Reed; Nura Mohamed
Journal:  Glob Cardiol Sci Pract       Date:  2014-12-31

Review 9.  Ion Channels in Pulmonary Hypertension: A Therapeutic Interest?

Authors:  Mélanie Lambert; Véronique Capuano; Andrea Olschewski; Jessica Sabourin; Chandran Nagaraj; Barbara Girerd; Jason Weatherald; Marc Humbert; Fabrice Antigny
Journal:  Int J Mol Sci       Date:  2018-10-14       Impact factor: 5.923

10.  PPARδ agonist GW501516 inhibits PDGF-stimulated pulmonary arterial smooth muscle cell function related to pathological vascular remodeling.

Authors:  Guangjie Liu; Xuan Li; Yan Li; Xin Tang; Jie Xu; Ran Li; Peng Hao; Yongchang Sun
Journal:  Biomed Res Int       Date:  2013-03-27       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.